Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Ktx-1001, a potent, selective MMSET/NSD2 inhibitor, enhances immunomodulatory and immune-directed therapies in preclinical models of multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVicki GambleEFErin Flynt

Discussion

Loading...

Member takes

Overview

Preclinical results demonstrate KTX-1001 improves tumor immune responses in multiple myeloma, enhancing efficacy of immunomodulatory drugs like pomalidomide and daratumumab.

Key Points

  • KTX-1001 significantly reduced cell viability in IMiD-resistant multiple myeloma cell lines when combined with pomalidomide.
  • At 5 nM pomalidomide, cell viability dropped from 84% to 33% with KTX-1001, demonstrating strong synergy.
  • Observational analysis of preclinical models indicates that KTX-1001 enhances the effects of immunomodulatory drugs and T-cell engagers.
  • These findings support the potential of KTX-1001 as a valuable treatment to augment tumor immune responses in multiple myeloma.

Cite This Study

Gamble et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1cahttps://doi.org/10.1182/blood-2025-7456
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)2025
  2. 2Enhancing immunotherapy efficacy in myeloma with a novel dual-action mitochondrial toxic peptide that overcomes resistance and induces immunogenic cell death.2025
  3. 3EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma2025 · 2 citations
  4. 4IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma2025
  5. 5Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma2025